BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Pfizer was once criticized for lack of vaccine development

<< Previous

Bullboard Posts

Next >>

Comment by moneywagonon Nov 21, 2024 11:08am

8 Views

Post# 36323836

RE:Pfizer was once criticized for lack of vaccine development

rich47 welcome I give your new member name the 1ST star for sharing your dd.
You may have a new member name but uhhhh mei thinks your a well seasoned wine/investor!! lol
LETS GOOOoooooooo BIOV, take me to da promise land wagons full of money!$$$$ lol
glta :>)

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3